IGFBPL1-Fusion Proteins: A Multi-targeted Approach for Retina that Promotes Neuroprotection & Mitigates Neuroinflammation
Time: 2:10 pm
day: Day Two
Details:
- Introducing IGFBPL1 and its interactions with two validated neuroscience targets: SORT1 and DCC/Netrin-1 receptor
- Discussing IGFBPL1-fusion proteins as first-in-class therapeutics being developed for glaucoma, Dry-AMD/GA, and other optic neuropathies, exhibiting both direct neuroprotective and anti-inflammatory pharmacologies
- Sharing IGFBPL1-based platform and its significant opportunity in neurodegenerative disorders of the brain